Tirzepatide — Research Evidence & Community Data
Also known as: Mounjaro, Zepbound, GIP/GLP-1 receptor agonist
Research & educational use only. This content is not medical advice. Consult a qualified healthcare professional before using any peptide compound.
What Is Tirzepatide?
Tirzepatide is a dual GIP and GLP-1 receptor agonist approved by the FDA (as Mounjaro for type 2 diabetes and Zepbound for chronic weight management). It is supported by large phase 3 randomized controlled trials demonstrating significant glycemic and weight outcomes. It is a prescription medication; non-prescription research-chemical sourcing carries substantial purity and safety risks.
Is Tirzepatide FDA Approved?
Tirzepatide is FDA approved.
What Does the Research Show?
As of 2026, there are 8 human randomized controlled trials with a combined 13,000 subjects, and 15 animal model studies. SURPASS (diabetes) and SURMOUNT (obesity) phase 3 programs show large, replicated benefits versus placebo and comparators. Among the strongest evidence bases of any compound discussed here.
| Study | Type | Subjects | Outcome | Source |
|---|---|---|---|---|
| Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1)Jastreboff AM, et al. · New England Journal of Medicine · 2022 | RCT | 2539 | Mean weight reduction up to ~20.9% at highest dose | DOI |
What Do Community Logs Show?
1 community protocol logs include Tirzepatide. Browse community logs →
How Is Tirzepatide Used in Research?
Mechanism of action. Dual agonism of GIP and GLP-1 receptors, enhancing glucose-dependent insulin secretion and reducing appetite.
Half-life. Approximately 5 days, enabling once-weekly administration.
Storage. Approved product: refrigerate; follow label. Research-chemical handling differs and is unverified.
Reconstitution. Approved products are pre-formulated. Reconstitution math applies only to lyophilized research material — not medical advice. See the reconstitution calculator — a math tool only, not dosing guidance.
What Does Tirzepatide's Evidence Tier Mean?
Tirzepatide is rated Tier 1 · RCT Evidence. Supported by human randomized controlled trials. Evidence tiers are a shorthand for how strong the human data is — Tier 1 reflects human randomized controlled trials, while lower tiers rest on observational, animal, or theoretical evidence. A higher tier means more confidence that observed effects are real and caused by the compound rather than by chance or bias. For how to weigh each tier, see our guide to understanding peptide evidence tiers.
How Do You Evaluate Tirzepatide Sourcing and Quality?
Because research-chemical Tirzepatide is unregulated, sourcing quality varies widely between sellers. Before trusting any supplier, check its reputation and enforcement history in the ranked list of trusted peptide sellers, and look for a batch-specific certificate of analysis (COA) showing third-party HPLC or LC-MS purity testing. Purity claims without a named lab, a batch number, and a method are marketing, not data. If you are reconstituting lyophilized material, the reconstitution calculator handles the arithmetic — it is a math tool only and not dosing guidance.
Where to Buy Tirzepatide: Trusted & Verified Sellers
Tirzepatide is supplied by specialist research-chemical sellers rather than pharmacies, so where you buy it matters as much as what you buy. The sellers below have published moderator-approved third-party lab results for Tirzepatide, ranked by overall reputation score. Always confirm a current batch-specific COA before purchasing.
PeptidesHub does not sell Tirzepatide or facilitate transactions — this list is for research transparency only.
How Are Adverse Reactions to Tirzepatide Reported?
Structured adverse-event reports help the whole community spot safety signals early. You can browse approved reports on the adverse events page or submit one yourself. For a serious or life-threatening reaction, seek medical care and report it to FDA MedWatch.
Frequently Asked Questions
Tirzepatide is FDA approved.